



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



C14 Ceramide (d18:1/14:0)

Item No. 22531

CAS Registry No.: 34227-72-0
Formal Name: N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-tetradecanamide
Synonyms: Cer(d18:1/14:0), C14 Ceramide, Ceramide (d18:1/14:0)
MF: C₃₂H₆₃NO₃
FW: 509.9
Purity: ≥95%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C14 Ceramide (d18:1/14:0) is supplied as a crystalline solid. A stock solution may be made by dissolving the C14 ceramide (d18:1/14:0) in the solvent of choice. C14 Ceramide (d18:1/14:0) is soluble in the organic solvent dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of C14 ceramide (d18:1/14:0) in DMF is approximately 0.15 mg/ml.

Description

C14 Ceramide is an endogenous ceramide generated by ceramide synthase 6.¹ During nutrient-deprivation-induced necroptosis in MEF cells, C14 ceramide levels increase in a time-dependent manner.² C14 ceramide plasma levels were reduced in obese patients with or without diabetes following a 12-week supervised exercise training program, correlating positively with weight and fat loss and negatively with an increase in insulin sensitivity.³ In contrast, plasma levels were higher in Parkinson's disease patients with dementia than those without dementia and higher levels were correlated with deficits in memory.⁴

References

1. Grosch, S., Schiffmann, and Geisslinger, G. Chain length-specific properties of ceramides. *Prog. Lipid Res.* **51(1)**, 50-62 (2012).
2. Sundaram, K., Mather, A.R., Marimuthu, S., *et al.* Loss of neutral ceramidase protects cells from nutrient- and energy-deprivation-induced cell death. *Biochem J.* **473(6)**, 43-55 (2016).
3. Kasumov, T., Solomon, T.P., Hwang, C., *et al.* Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. *Obesity (Silver Spring)* **23(7)**, 1414-1421 (2015).
4. Xing, Y., Tang, Y., Zhao, L., *et al.* Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia. *J. Neurol. Sci.* **370**, 82-87 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/25/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM